Funding Opportunities
The following NIH funding opportunities have been brought to our attention. These may be applicable to research using NHLBI Biorepository and/or Data Repository resources.
These funding opportunities are not administered by the BioLINCC program. Inquiries regarding research topic eligibility and other administrative matters should be directed to the staff offices identified in the announcements. However, BioLINCC staff will be pleased to provide assistance if needed to search for suitable repository resources for the proposed research. To search for studies or submit a request for resources available through BioLINCC, follow the instructions on the Studies page.
NHLBI Big Data Analysis Challenge: Creating New Paradigms for Heart Failure Research
The NHLBI is inviting novel Solutions for the NHLBI Big Data Analysis Challenge: Creating New Paradigms for Heart Failure Research. The goal of the challenge is to foster innovation in computational analysis and machine learning approaches utilizing large-scale NHLBI-funded datasets to identify new paradigms in heart failure research. The challenge aims to address the need for new open source disease models that can define sub-categorizations of adult heart failure to serve as a springboard for new research hypotheses and tool development in areas of heart failure research from basic to clinical settings.
NHLBI will award up to a total of $250,000. Up to five (5) winners will be selected, with each winning up to $50,000. The competition period ends at NOON EDT on August 28, 2020.
For more information on this challenge please visit:
www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/NHLBI-heart-failure-data-challenge
Maximizing the Scientific Value of Existing Biospecimen Collections (R21)
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute's (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. While other publicly available repositories would be considered, depending on analyses to be conducted, nationally representative analyses will receive priority. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.
The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).
For more information on RFA-OD-19-021 please visit:
https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-021.html
PA-18-741 Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21)
This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.
For more information on PA-18-741 please visit:
https://grants.nih.gov/grants/guide/pa-files/PA-18-741.html
PAR-20-078 Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21)
The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection. It will not support the collection of new data.
For more information on PAR-20-078 please visit:
https://grants.nih.gov/grants/guide/pa-files/PAR-20-078.html
Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21)
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.).
The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).
For more information on RFA-OD-19-022 please visit:
https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-19-022.html
Notice of Special Interest (NOSI): IDEA2Health: Innovative Data Evaluation and Analysis to Health (Parent R01)
The purpose of this Notice of Special Interest (NOSI) is to inform applicants to the National Heart, Lung, and Blood Institute (NHLBI) of an area of special interest in the development and utilization of data science methodologies for gaining new insights to improve health in heart, lung, blood or sleep (HLBS) domains. Applications in response to this Notice must be submitted through the NIH Parent Announcement PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
For more information on NOT-HL-19-712 please visit:
https://grants.nih.gov/grants/guide/notice-files/NOT-HL-19-712.html